 |
|
|
Further Information for Customers and Patients |
What do I do if a customer informs me a patient being treated with EPREX/ERYPO has experienced loss of effect (LOE)? These cases must be reported immediately to Medical Affairs Department for management by the established Drug Safety & Surveillance procedure. What do I do if a customer informs me that they believe a patient has PRCA or anti-EPO antibodies? These cases must be reported immediately to Medical Affairs Department for management by the established Drug Safety & Surveillance procedure. Is there a Company website with more information about LOE, PRCA and anti-EPO antibodies? A health care professionals website for information updates is planned to launch shortly. Additional information will be forthcoming from Medical Affairs and the Operating Company Marketing Department. Will the Company be talking about this at medical congresses? We will be increasing the scientific dialog about the PRCA and anti-EPO antibody issue because it is a scientifically intriguing phenomenon and has patient care implications. Our intention is to ensure that the medical community is presented a clear, fair balanced and appropriate perspective about this very rare event. Will we continue to update our customers regarding our investigations? Global Commercial updates like this one will be provided as appropriate to Operating Companies. Customer updates are available through multiple sources: Company employee contacts to customers, Medical Inquiries to the Company, publications, Medical Congress Proceedings, Healthcare professional Website (TBD). If my customer asks a question not answered by this Background Packet, what should I do? All inquiries about product performance, safety, etc., should be referred to your Medical Affairs Department. If we receive an inquiry from the Media or from Investment Analysts, how should we handle requests for PRCA information? All media contacts will be handled by J&J Global Pharmaceutical Communications. In the event an Operating Company receives a call or request for information from a member of the media on this matter, please immediately contact one of the individuals listed here for guidance on media response statements: Carol Goodrich (GPC/Raritan)
Daniel De Schryver (GPC/Beerse)
Please use the attached Media Log Form to collect information from the caller. Please submit by telefax this form as indicated. The form is found in Appendix. Calls from Analysts should be directed to: Helen Short
|
 |